Euro Retina Programme Virtual 2021 - RETINA FORUM VIRTUAL Weds. 08 September - OPHTHALMOLOGY FUTURES ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
RETINA FORUM
VIRTUAL
Weds. 08 September
ednesday 30 September
Euro Retina Programme
Virtual 2021
Vision, a window to the world.
With vision, we connect with others.
With vision, we feel happiness.
That is why we at Santen believe
seeing is integral to life.
As a company focused on vision,
we explore and grow the unlimited potential
of our ability to see.
Because we know we can one day
achieve a world free of vision problems.
Because we know we can one day
create a future full of smiles
where everyone’s vision is nurtured.
Until then, we will not stop challenging ourselves.
EURO RETINA VIRTUAL FORUM 2021 1
CONTENTS:
RETINA PROGRAMME
Welcome 3
Timings 4
Speakers
Presenting companies | Pannelists | Chairs 6
Our sponsors 7
Platinum 9
Gold 10
Silver 11
Bronze 12
New innovator 13
European Forum 2021 14
Programme committee 15
EURO RETINA VIRTUAL FORUM 2021 2
WELCOME:
RETINA VIRTUAL FORUM
Dear colleagues,
Welcome to the Ophthalmology Futures Retina This Forum will highlight developments in the
Forum 2021. The virtual format for this year's treatment of Dry AMD, home monitoring,
forum has presented us with challenges and surgical robotics and personalized approaches
opportunities. While missing the chance to for posterior segment diseases.
network with participants in person, we are We will look to the future of drug delivery as
able to reach a much larger audience and well as gene therapy for rare and common
include speakers who would otherwise not have retinal diseases. An interview with Dr. Anthony
been able to attend. Adamis will undoubtedly be one of the
highlights of the day.
The unique nature of innovation relating
to diseases of the posterior segment led us to Ophthalmology Futures Forums thanks our key
recognize the need for a standalone forum advisors, corporate presenters and distinguished
to increase our focus in this rapidly evolving faculty for their invaluable support and
space a few years ago and we have been assistance. We would also like to especially
delighted by the success of this format. thank our sponsors who have provided support
As in prior Retina forums, we will have allowing us to have this meeting without
presentations from companies at various stages a registration fee for all attendees!
of the innovation process and panels on topics
Thank you for joining us!
deemed to be of interest to all stakeholders.
Ophthalmology Futures is dedicated to creating The Ophthalmology Futures Team
a novel program for each meeting.
Vision Futures Limited, London, UK.
Registered in England No: 8125858.
EURO RETINA VIRTUAL FORUM 2021 3
TIMINGS:
RETINA VIRTUAL FORUM
TIMMINGS ARE IN CENTRAL EUROPEAN SUMMER TIME
13:50 - 14:00 18:10 - 18:40
WELCOME PANEL 5: HOME MONITORING
• Keith Barton
& REAL WORLD DATA
TO ACCELERATE POSTERIOR
• Kuldev Singh
SEGMENT INNOVATION
Co-chairs
14:00 - 14:30 • Francesco Bandello
• Usha Chakravarthy
PANEL 1: PERSONALIZED
APPROACH TO BACK OF Panellists
THE EYE THERAPEUTICS • Art Ciociola
• Kester Nahen
Chair
• Helge Sudkamp
• Adnan Tufail
• Angelo Rago
Panellists • Sally Tucker
• Jill Hopkins • Einar Stefánsson
• Daniela Ferrara • David Crabb
• Jay Duker
• Jason Ehrlich
• Almira Chabi 18:40 - 19:10
• Einar Stefánsson
PANEL 6: SUSTAINED
DRUG DELIVERY FOR AMD:
MAINSTREAM CARE OR AN
14:30 - 15:00 EXPENSIVE SIDE SHOW?
PANEL 2: GENE THERAPY
Co-chairs
& GENE EDITING FOR RARE
• Ursula Schmidt-Erfurth
& COMMON RETINAL DISEASES
• Ramin Tadayoni
Co-chairs Panellists
• Bart Leroy
• Jaya Chidambaram
• Dominik Fischer
• Cynthia Grosskreutz
Panellists
• Ram Palanki
• Olivier Danos
• Fred Guerard
• Magali Taiel
• Gil Carrasquinho
• Thomas Ciulla
19:10 - 19:30
ONE ON ONE
15:00 - 16:00 • Kuldev Singh
COMPANY PRESENTATIONS 1 • Anthony Adamis
• REGENXBIO | Stephen Pakola
• GenSight Biologics S.A. | Magali Taiel
19:30 - 20:30
• Eyevensys | Francine Behar-Cohen
• Iveric Bio | Pravin Dugel COMPANY PRESENTATIONS 3
• Santen Cell Therapy | Gil Carrasquinho • Clearside Biomedical | Thomas Ciulla
• ForwardVue Pharma | Alan Franklin • EyePoint Pharmaceuticals | Nancy Lurker
• Re-Vana Therapeutics | Michael O'Rourke
• Samsara Vision | Mike Besserman
• Preceyes | Gerrit Naus
16:00 - 16:30
PANEL 3: DRY AMD THERAPY:
WILL WE GET THERE 20:30 - 21:00
& WHO WILL PAY?
PANEL 7: SURGERY
Co-chairs AND ROBOTICS:
• Sophie Bakri THE NEXT FRONTIER?
• Sobha Sivaprasad
Co-chairs
Panellists
• Stan Rizzo
• Keith Lane
• Borja Corcostegui
• Chris Brittain
Panellists
• Melissa Liew
• Paul Hallen
• Pravin Dugel
• Gregg Draudt
• Kourous Rezaei
• Steve Charles
• Paulo Stanga
• Eugene de Juan
16:30 - 17:10
PANEL 4: INVESTMENT
OVERVIEW 21:00 - 21:10
Introduction SUMMARY
• Michael Giaquinto
• Adnan Tufail
Chair
• Michael Giaquinto
Panellists
21:10 - 21:15
• Geert-Jan Mulder
• Begoña Carreño SUMMARY & CONCLUDING
• Alex Pasteur
COMMENTS
• Eugene de Juan • Keith Barton
• Kuldev Singh
17:10 - 18:10
COMPANY PRESENTATIONS 2
• Ocuphire Pharma | Mina Sooch
• OcuTerra Therapeutics | Kerrie Brady
• Pleryon Therapeutics | Yu Yu
• MONA.health | Olivier Menage
• Notal Vision Ltd | Kester Nahen
• Visotec GmbH | Helge Sudkamp
EURO RETINA VIRTUAL FORUM 2021 4
VISUAL FREEDOM IN ONE EXCEPTIONAL LENS
ASTIGMATISM
MYOPIA
The Visian Toric ICL clinical trial reported 1:
• 98.4% of patients would have the Visian Toric ICL procedure again
• Predictable outcomes realized across a broad range of treatment options
• 93.8% of eyes maintained or gained 1 or more lines of BSCVA
• Rapid and stable achievement of outstanding MRSE and MRCyl
• In eyes with pre-op BSCVA 20/20 or better 100% of eyes obtained 20/40 or better UCVA
• Over 94% of eyes maintained rotational stability of ≤ 5˚ at all post - op time points
1 STAAR Surgical Visian Toric Implantable Collamer Lens PMA Supplement P030016 Ophthalmic Devices Advisory Panel, March 14, 2014
SPEAKERS: P
RESENTING COMPANIES
PANNELISTS & CHAIRS
CHAIRS & PANELLISTS PRESENTING
COMPANIES
A K
• Adnan Tufail • Keith Barton A
Consultant Ophthalmic Consultant, Moorfields Eye
• Alan Franklin
Surgeon, Moorfields Eye Hospital NHS Foundation Trust.
Founder, ForwardVue Pharma
Hospital NHS Foundation Trust Professor of Ophthalmology,
• Alex Pasteur UCL
Partner, F-Prime Capital • Keith Lane
• Almira Chabi Vice President, Ora, Inc. F
VP, Glaucoma & • Kester Nahen
• Francine Behar-Cohen
Neuroprotection; AI Lead, CEO, Notal Vision Ltd.
Scientific Founder, Eyevensys
Santen Pharmaceutical Co. Ltd. • Kourous Rezaei
• Angelo Rago Associate Professor, Illinois
Global Head of Ophthalmic Retina Associates/Rush
Diagnostics, Carl Zeiss University Medical Center G
Meditec, Inc. • Kuldev Singh • Gerrit Naus
• Anthony Adamis Professor of Ophthalmology, CEO, Preceyes B.V.
Formerly Vice President Stanford University School of
& Global Head of Medicine • Gil Carrasquinho
Ophthalmology, Genentech Head of Cell Therapy, Santen
Pharmaceutical Co., Ltd
• Arthur Ciociola
Vice President Global
Head Regulatory Affairs M
Ophthamology, Novatis
Pharma AG
• Magali Taiel H
CMO, GenSight Biologics S.A.
• Helge Sudkamp
• Melissa Liew CEO, Visotec GmbH
VP & Global Head of
B Translational Medicine-
Ophthalmology, Novartis
• Bart Leroy
Professor of Ophthalmology,
Intitutes for Biomedical
Research
K
Ghent University Hospital • Kerrie Brady
CEO, OcuTerra Therapeutics
• Begoña Carreño
• Kester Nahen
Global Head BDL
Ophthalmology, Novartis O CEO, Notal Vision Ltd
Pharma AG • Olivier Danos
Senior Vice President, Chief
Scientific Officer, REGENXBIO
M
C • Magali Taiel
CMO, GenSight Biologics S.A.
• Chris Brittain
Global Head of Ophthalmology P • Michael O'Rourke
Product Development, • Paul Hallen CEO, Re-Vana Therapeutics
Genentech VP, Global Head Retina, Alcon
• Mike Besserman
• Cynthia Grosskreutz • Paulo Stanga VP, Worldwide Marketing,
VP & Global Head of Professor of Ophthalmology, Samsara Vision
Ophthalmology, Novartis London Vision Clinic - Retina
Intitutes for Biomedical • Mina Sooch
• Pravin Dugel CEO, Ocuphire Pharma
Research
President, Iveric Bio
D N
R • Nancy Lurker
• Daniela Ferrara
• Ram Palanki President & CEO, EyePoint
Senior Medical Director,
Senior Vice President, Pharmaceuticals
Roche-Genentech
REGENXBIO
• David Crabb
• Ramin Tadayoni
Professor of Visual Science,
Head of Ophthalmology
City University of London
Department, Hôpitaux De Paris O
• Dominik Fischer
• Olivier Menage
Professor of Ophthalmology,
CEO, MONA.health
University of Tuebingen
S
• Sally Tucker
E Executive Director, Ora, Inc. P
• Sobha Sivaprasad • Pravin Dugel
• Einar Stefánsson
Consultant Ophthalmologist, President, IVERIC bio
Professor, University of Iceland
Moorfields Eye Hospital NHS
• Eugene De Juan Foundation Trust
Managing Partner, ForSight
Labs
• Sophie Bakri
Professor, Mayo Clinic
T
• Stano Rizzo • Thomas Ciulla
Professor of Ophthalmology, CMO, Clearside Biomedical, Inc.
F University of Florence
• Francesco Bandello • Steve Charles
Professor, University CEO & Founder, Charles Retina
Institute
S
Vita-Salute
• Stephen Pakola
• Fred Guerard
Senior Vice President and
CEO, Graybug Vision
CMO, REGENXBIO
T
• Thomas Ciulla
G CMO, Clearside Biomedical,
Y
Inc.
• Geert-Jan Mulder
• Yu Yu
Managing Partner,
CEO, Pleryon Therapeutics
Forbion Capital Partners
• Gil Carrasquinho U
Head of Cell Therapy, Santen
• Ursula Schmidt-Erfurth
Pharmaceutical Co., Ltd
Professor & Chair, Medical
• Gregg Draudt University of Vienna
Director of Design, Cambridge ALL OF THE SPEAKERS FOR
• Usha Chakravarthy
Consultants OUR EURO RETINA FORUM
Professor, The Queen's
Univeristy of Belfast CAN BE FOUND ON OUR
WEBSITE:
H OPHTHALMOLOGY-
• Helge Sudkamp
CEO, Visotec GmbH
FUTURES.COM/FORUMS
J
• Jason Ehrlich
CMO/CFO, Kodiak Sciences, Inc.
• Jay Duker
Chief Strategic Scientific
Officer, EyePoint
Pharmaceuticals
• Jaya Chidambaram
Medical Director, Roche-
Genentech
• Jill Hopkins
Global Head Ophthalmology
Development, Novartis
Pharma AG
EURO RETINA VIRTUAL FORUM 2021 6
SPONSORS: EURO FORUMS 2021
THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY
PRESENTATIONS AND DELEGATE REGISTRATION IS COMPLIMENTARY FOR EVERYONE.
EURO RETINA VIRTUAL FORUM 2021 7
PLATINUM
Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With
our 70-plus-year heritage, we are the largest eye care device company in the world – with
complementary businesses in Surgical and Vision Care. Being a truly global company, we
work in over 70 countries and serve patients in more than 140 countries. We have a long
history of industry firsts, and each year we commit a substantial amount in Research and
Development to meet customer needs and patient demands.
For more information, please visit www.alcon.com
As a global specialized company dedicated exclusively to ophthalmology, Santen brings
130-year history of scientific knowledge and organizational capabilities to research,
development, and commercialization of pharmaceutical, surgical, and OTC eye care
products. Headquartered in Osaka, Japan, Santen is the market leader in Japan for
prescription ophthalmic pharmaceuticals. With more than 4,000 employees worldwide,
Santen continues to grow its global presence across Asia, Europe, and North America,
providing innovative solutions in retina, glaucoma, uveitis, dry eye, ocular allergy and
infection to patients around the world.
For more information, please visit www.santen.com
EURO RETINA VIRTUAL FORUM 2021 9GOLD
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs,
develops, manufactures and markets implantable lenses for the eye with companion
delivery systems. These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens
used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes
the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted
to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL
go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates
manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau,
Switzerland.
For more information, please visit the Company’s website at www.staar.com
Helping Doctors Improve
Their Patients‘ Quality of Life.
ZEISS Medical Technology Business Group
Improving Quality of Life
ZEISS Medical Technology is proud
to support the Ophthalmology
Futures Retina Forum
www.zeiss.comSILVER
Essilor International is the world’s leading ophthalmic optics company. Essilor designs,
manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission
is to improve lives by improving sight. To support this mission, Essilor allocates more than €200
million to research and innovation every year, in a commitment to continuously bring new, more
effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™,
Xperio®, Foster Grant®, and Bolon™. It also develops and markets equipment, instruments and
services for eyecare professionals.
At Essilor we believe that people deserve the right vision solutions to unleash the full potential
of their life, every day, all life long. That belief is anchored in the Group's mission. Essilor
International is a subsidiary of EssilorLuxottica.
Please visit: www.essilor.com
REGENXBIO Inc. is a leading clinical-
stage biotechnology company seeking
to improve lives through the curative
potential of gene therapy. Our gene
therapy product candidates are designed to
deliver functional genes to address genetic
defects in cells, enabling the production
of therapeutic proteins or antibodies that
are intended to impact disease. Through a
single administration, gene therapy could
potentially alter the course of disease The Medical Technology segment of ZEISS
significantly and deliver improved patient offers complete solutions to diagnose and
outcomes with long-lasting effects. We treat ophthalmic diseases. With a special
have developed a broad pipeline of focus on ophthalmology and ophthalmic
gene therapy programs using our NAV® surgery, the company supports healthcare
Technology Platform to address genetic professionals in setting new standards of
diseases through two modalities: AAV- care with proven medical technology and
mediated antibody delivery and monogenic broad application competence based on
gene replacement. We believe this platform cutting-edge innovations.
forms a strong foundation for our current
For more information, please visit
programs and with our ongoing research
www.zeiss.com/meditec/int/about-us.html
and development, we expect to continue to
expand the platform.
Please visit www.regenxbio.com
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global
medicines company, we use innovative science and digital technologies to create transformative
treatments in areas of great medical need. In our quest to find new medicines, we consistently
rank among the world’s top companies investing in research and development. Novartis products
reach nearly 800 million people globally and we are finding innovative ways to expand access
to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis
around the world.
Please visit: www.novartis.com
EURO RETINA VIRTUAL FORUM 2021 11BRONZE
GenSight Biologics is a clinical-stage biopharma company focused on developing and
commercializing innovative gene therapies for retinal neurodegenerative diseases and central
nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms,
the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in
patients suffering from blinding retinal diseases.
Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics’ lead
product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is currently in the review phase
of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.
Our second lead product candidate, GS030, combines gene therapy with optogenetics and is
currently in Phase I/II PIONEER to treat Retinitis Pigmentosa (RP).
For more information, please visit www.gensight-biologics.com
LENSAR®, Inc., the leader in next-generation
femtosecond cataract laser technology,
continues to focus on astigmatism with
Streamline® IV. This includes enhancements
Iveric Bio is a science-driven biopharmaceutical unique to LENSAR that are dedicated to help
company focused on the discovery and surgeons confidently manage astigmatism and
development of novel treatment options for optimize patient outcomes, for both toric IOLs
retinal diseases with significant unmet medical and arcuate incisions.
needs. The Company is currently developing
Enhancements include IntelliAxis Refractive
both therapeutic product candidates for
Capsulorhexis®, which incorporates lenticular
age-related retinal diseases and gene therapy
markings to guide precise and confident
product candidates for orphan inherited
toric IOL alignment, and wireless transfer
retinal diseases.
of preoperative data from multiple devices,
For more information on the Company, for seamless treatment planning. Iris
please visit www.ivericbio.com registration further contributes to accuracy
by automatically accounting for cyclotorsion.
The LENSAR Laser is revolutionizing the
surgeon’s ability to deliver great outcomes for
astigmatic patients.
Please visit www.lensar.com
Ora is the world's leading full-service ophthalmic research organization with offices in the United
States, United Kingdom, Australia, and Asia. For over 40 years, we have helped our clients earn 48
product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical
and device companies, to efficiently bring their new products from concept to market. Ora's unique
models, methodologies, and global regulatory strategies have been refined and proven across
thousands of global projects. We bring together the world's most extensive and experienced team of
ophthalmic experts to maximize the value of new product initiatives.
For more information, please visit www.oraclinical.com
Apellis is a global biopharmaceutical
company leveraging courageous science,
creativity, and compassion to deliver
AcuFocus, Inc., is a privately held ophthalmic life-changing medicines.
medical device company that delivers At Apellis, we are committed to developing
breakthrough small aperture intraocular transformative therapies for people
products to address diverse unmet needs living with Geographic Atrophy (GA) by
and help patients achieve their best personal regulating complement, a part of the body’s
vision. The IC-8 IOL is a first-of-its-kind immune system.
presbyopia-correcting lens that delivers Our work is rooted centrally at C3, which is
true extended depth of focus and enhanced the only target in the complement cascade
adaptability through its distinctive, wavefront- that addresses all three pathways that can
filtering, small aperture design. The IC-8 IOL drive disease. Targeting C3 has broad platform
received CE mark in 2015 and is available in potential to treat many diseases such as
select markets across Europe and Asia. GA, where there are currently no treatment
Visit www.AcuFocus.com for more options available.
information. Please visit: www.apellis.eu
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and
commercializing innovative therapeutics to help improve the lives of patients with serious eye
disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended
intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal
anti-VEGF treatment initially targeting wet AMD, the leading cause of vision loss among people
50 years of age and older in the United States. EyePoint’s product candidate pipeline also includes
YUTIQ® 50, a potential twice-yearly treatment for non-infectious uveitis affecting the posterior
segment of the eye, and separately, two commercial products, YUTIQ and DEXYCU.
Please visit: www.eyepointpharma.com
Sight Sciences is a growth-stage medical device company dedicated to the development
of intelligently designed and engineered products that address the underlying physiology
of ophthalmic diseases. The company's portfolio consists of the OMNI® Surgical System which
is a novel, implant-free device that can be used in combination with cataract surgery or as
a standalone procedure, as well as the non-surgical TearCare® System which is a device that
applies heat to the eyelids to remove blockage, the hallmark of MGD.
Please visit: www.sightsciences.com
EURO RETINA VIRTUAL FORUM 2021 12NEW INNOVATORS
LensGen®, a clinical stage ophthalmic medical device company headquartered in Irvine, California
has developed a disruptive fluid-optic intraocular lens (IOL) for treating cataracts and presbyopia.
With its innovative Juvene® IOL the company aims to bring to market this revolutionary device
designed to restore full range of vision with quality optics and improved safety due to the modular,
capsule filling design. The company is currently progressing through the IDE approval process and
is planning a large Series B Financing in early 2021 that will fund the company through approval of
the Juvene IOL pivotal FDA study.
For more information about the financing please contact Ramgopal Rao, CEO at rrao@lensgen.com
and visit www.lensgen.com
Graybug is a clinical-stage biopharmaceutical iSTAR Medical pioneers
company focused on developing transformative minimally invasive, ophthalmic
medicines for the treatment of diseases of implants for powerful, safe and
the retina and optic nerve. The company’s enduring treatment of patients
proprietary ocular delivery technologies are with glaucoma. MINIject is
designed to maintain effective drug levels in a supraciliary MIGS device made
ocular tissue for six months and potentially from STAR® material, which is
longer, improving disease management, reducing soft and flexible, medical-grade
healthcare burdens and ultimately delivering silicone with a micro-porous,
better clinical outcomes. Graybug’s lead product multi-channel geometry enabling
candidate, GB-102, a microparticle depot bio-integration of surrounding
formulation of the pan-vascular endothelial tissues. Clinical trials show that
growth factor (VEGF) inhibitor, sunitinib malate, IOP is reduced by >40% to a mean
targeting a six-month or longer dosing regimen, of 13.8mmHg at two years post-
inhibits multiple neovascular pathways for surgery.
the intravitreal treatment of retinal diseases,
The US Food and Drug
including wet age-related macular degeneration.
Administration (FDA) has
Graybug is also using its proprietary technologies
approved the start of a pivotal
to develop GB-401, an injectable depot
trial for MINIject.
formulation of a beta-adrenergic blocker
prodrug, for primary open-angle glaucoma, with Please visit: www.istarmed.com
a dosing regimen of once every six months or
longer, and GB-103, a longer-acting version of
GB-102, designed to maintain therapeutic drug
levels in the retinal tissue for 12 months with
a single injection. Founded in 2011 on the basis
of technology licensed from the Johns Hopkins
University School of Medicine, Graybug is
headquartered in Redwood City, California.
For more information, please visit
www.graybug.vision or contact us at
info@graybug.vision.
A new name in the ophthalmic industry, Medevise Consulting brings together an experienced
team to provide regulatory, clinical, market assessment and medical communication services for
companies looking to succeed in Europe.
With unparalleled insight, resources and a network built up over decades of experience, we
work with clients to build long-term relationships that ensure your European business thrives.
As a team of specialists, we stand for ophthalmology innovation in Europe.
Please visit: www.medevise.com
EURO RETINA VIRTUAL FORUM 2021 13SAVE THE DATE
EUROPEAN VIRTUAL FORUMS
European Forum Virtual 2021
Thurs. 07 October
(Forums begin @ 12:30 Central European Summer Time)
www.ophthalmology-futures.com
SEEKING TO IMPROVE LIVES
THROUGH THE CURATIVE
POTENTIAL OF GENE THERAPY
OUR COMMITMENT
REGENXBIO is committed to developing gene therapies that improve
treatment options for people with serious diseases. The personal stories of
patients and families help guide our work. We earn their trust through our
actions and our words.
REGENXBIO.com › For the latest updates on our programs, visit REGENXBIO.com
©2021 REGENXBIO Inc. All rights reserved.PROGRAMME COMMITTEE
Ike Ahmed | Division Head, Ophthalmology, Sir Peng Khaw | Professor of Glaucoma & of Ophthalmology, Quinze- Vingts National
Trilium Health Partners, Toronto, Canada. Ocular Healing, Director National Institute for Ophthalmology Hospital & Rothschild
Assistant Professor, University of Toronto, Health Research Biomedical Research Centre, Ophthalmology Foundation, Paris. Director,
Canada. Clinical Assistant Professor, University Moorfields Eye Hospital & UCL Institute of Institut de la Vision (Sorbonne Université,
of Utah, USA. Ophthalmology, London, UK. Inserm, CNRS, Paris).
Jorge Alio | Professor &Chairman of Shigeru Kinoshita | Professor & Chair, Chelvin Sng | Associate Professor,
Ophthalmology, Miguel Hernandez University, Department of Ophthalmology, Kyoto Department of Ophthalmology, National
Alicante, President, Vissum Corporation, Prefectural University of Medicine, Japan. University Hospital, Singapore.
Spain.
Richard Lindstrom | Founder & Attending Julian D. Stevens | Consultant Ophthalmic
Gerd Auffarth | Professor & Chairman, Surgeon: Minnesota Eye Consultants, Surgeon, Moorfields Eye Hospital, London,
Dept. of Ophthalmology, University Minneapolis, USA. Adjunct Professor Emeritus: UK.
of Heidelberg.Director, David J. Apple University of Minnesota, USA.
Donald Tan Tiang Hwee | Arthur Lim
International Laboratory for Ocular Pathology,
Boris Malyugin | Chief of Department of Professor, SNEC & Duke-NUS Medical School,
International Vision Correction Research
Cataract & Implant Surgery, Deputy Director Singapore. Partner & Senior Consultant
Centre, Heidelberg, Germany.
General, S. Fyodorov Eye Microsurgery Ophthalmic Surgeon, Eye & Retina Surgeons
Francesco Bandello | Full Professor & Complex State Institution, Moscow, Russia. (ERS), Camden Medical Centre, Singapore.
Chairman Department of Ophthalmology,
Prof David Spalton | Past-president, Marie-Jose Tassignon | Past Chief & Chair
University Vita-Salute, Ospedale San Raffaele
European Society of Cataract & Refractive Department of Ophthalmology Antwerp
of Milan, Italy.
Surgeons London, UK. University & University Hospital Antwerp,
David Chang | Altos Eye Physicians & Belgium.
Prof Dr Ingeborg Stalmans | Head of
Clinical Professor, University of California,
the Glaucoma Clinic, University Hospitals Adnan Tufail | Consultant Ophthalmologist,
San Francisco, USA.
UZ Leuven, Belgium. Head, Ophthalmology Moorfields Eye Hospital, London, UK.
Steve Charles | Founder & CEO, Charles Research Group, University KU Leuven, Professor, UCL Institute of Ophthalmology,
Retina Institute Clinical Professor of Belgium. London, UK.
Ophthalmology, University of Tennessee, USA.
Paulo Eduardo Stanga | London Vision Tien Yin Wong | Vice Dean, Academic &
Paul Chew | Professor of Ophthalmology, Clinic Retina Lead Consultant Ophthalmologist Clinical Development, Duke-NUS Medical
National University of Singapore, Singapore. & Vitreoretinal Surgeon. Professor of School, Singapore. Provost’s Chair Professor,
Ophthalmology & Retinal Regeneration, National University of Singapore. Deputy
Beatrice Cochener | Professor, Chairman,
University of Manchester, UK. Group CEO (Research & Education),
Ophthalmology Department, University
SingHealth, Singapore. Medical Director &
Hospital, Brest, France. Past-president, Paul Rosen | Consultant Ophthalmic
Senior Consultant Ophthalmologist, Singapore
European Society of Cataract & Refractive Surgeon, Oxford Eye Hospital, Oxford, UK.
National Eye Centre. Chair, Ophthalmology &
Surgeons.
José-Alain Sahel | Endowed Professor & Visual Sciences Academic Clinical Programme.
Jost Jonas | Professor of Ophthalmology, Chairman, Department of Ophthalmology, Chairman, Board of Directors, Singapore Eye
Medical Faculty Mannheim, University of University of Pittsburgh Medical Center, Research Institute, Singapore.
Heidelberg, Germany. Pittsburgh, USA. Professor of Ophthalmology,
Sorbonne Université. Chairman Departments
ORGANISING
ADVISORS COMMITTEE
Laurent Attias | Senior VP, Head of Malvina Eydelman | Director, Division of Keith Barton | Consultant Ophthalmologist,
Strategy, BD&L & Market Access, Alcon, USA. Ophthalmic & Ear, Nose & Throat Devices Moorfields Eye Hospital, London, UK,
ODE/CDRH/FDA, USA. Professor of Ophthalmology, UCL, UK.
Eugene de Juan | Jean Kelly Stock
Distinguished Chair, Ophthalmology, ForSight Akira Kurokawa | Chairman. Santen Don Budenz | Professor & Chairman,
Labs & University of California, Menlo Park, Pharmaceutical Co. Department of Ophthalmology, University of
California. North Carolina, USA.
James Mazzo | JGlobal President
Tom Dunlap | Founder, Dunlap Ophthalmic Devices, Carl Zeiss Meditec, USA. Lea Pietrolongo | Operational Director,
Ophthalmology Consulting, Board of Ophthalmology Futures Forums, UK.
Naveed Siddiqi | Novo Ventures.
Directors, Advisory Boards.
Kuldev Singh | Professor of Ophthalmology
& Director, Glaucoma Service, Stanford
University Medical Center, Palo Alto, USA.
Chelvin Sng | Associate Professor,
Department of Ophthalmology, National
University Hospital, Singapore.
Sanny Yuzhen Jiang | Honorary
Clinical Fellow. Moorfields Eye Hospital.
Senior Research Associate, University College
London Institute of Ophthalmology, UK.
EURO RETINA VIRTUAL FORUM 2021 15We Help People
See Brilliantly.
At Alcon, we aspire to lead the world in innovating life-changing vision
products because when people see brilliantly, they live brilliantly.
Each year our products touch the lives of millions of people living
with conditions like cataracts, retinal diseases, and refractive errors.
We offer the most complete line of ophthalmic surgical devices,
as well as a differentiated contact lens and lens care portfolio
to help patients see, look and feel their best.
At Alcon, we are at the forefront of innovation,
partnering with eye care professionals to bring
the gift of sight to more people around the world.
That’s been our legacy for more than 70 years—
and as the new Alcon, it’s what guides our
focus towards the brilliant future ahead.
Learn more at alcon.com
CONNECT WITH US!
@AlconEyeCare
@AlconCareers
@Alcon
@AlconLife
© 2021 Alcon Inc. 03/21 2103A164
EURO RETINA VIRTUAL FORUM 2021 16You can also read
